Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Lachmann

Showing results (191-200 of 426) with videos related to

Pageof 43
Sort By:
Haematologica|February 5, 2008
Efficacy of bortezomib in systemic AL amyloidosis with relapsed/refractory clonal diseaseAshutosh D Wechalekar, Helen J Lachmann, Mark Offer, et al.
Clinical and Experimental Rheumatology|June 30, 2015
Therapeutic blockade of interleukin-6 by tocilizumab in the management of AA amyloidosis and chronic inflammatory disorders: a case series and review of the literatureThirusha Lane, Julian D Gillmore, Ashutosh D Wechalekar, et al.
Journal of Neuroimmunology|January 1, 1985
Immunological studies on the cerebrospinal fluid in neurological sarcoidosisJ D Mitchell, P L Yap, L A Milne, et al.
Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology|September 1, 1995
Bee venom immunotherapy induces a shift in cytokine responses from a TH-2 to a TH-1 dominant pattern: comparison of rush and conventional immunotherapyS M McHugh, J Deighton, A G Stewart, et al.
Clinical and Experimental Immunology|September 30, 2015
Further studies of the down-regulation by Factor I of the C3b feedback cycle using endotoxin as a soluble activator and red cells as a source of CR1 on sera of different complotypeP J Lachmann, E Lay, D J Seilly, et al.
The Journal of Experimental Medicine|June 1, 1993
Complement-mediated adipocyte lysis by nephritic factor seraP W Mathieson, R Würzner, D B Oliveria, et al.
Vox Sanguinis|January 1, 1983
Use of monoclonal anti-C3 antibodies to characterise the fragments of C3 that are found on erythrocytesP J Lachmann, D Voak, R G Oldroyd, et al.
Clinical and Experimental Immunology|April 1, 1978
The immunogloblin nature of nephritic factor (NeF)D M Scott, N Amos, J G Sissons, et al.
Clinical and Experimental Immunology|September 1, 1992
C7 M/N protein polymorphism typing applied to inherited deficiencies of human complement proteins C6 and C7R Würzner, N Rance, P C Potter, et al.
Clinical and Experimental Immunology|July 1, 1985
Simultaneous turnover of normal and dysfunctional C1 inhibitor as a probe of in vivo activation of C1 and contact activatable proteasesP Woo, P J Lachmann, R A Harrison, et al.
Pageof 43

Showing results (191-200 of 426) with videos related to

Sort By:
Pageof 43
Haematologica|February 5, 2008
Efficacy of bortezomib in systemic AL amyloidosis with relapsed/refractory clonal diseaseAshutosh D Wechalekar, Helen J Lachmann, Mark Offer, et al.
Clinical and Experimental Rheumatology|June 30, 2015
Therapeutic blockade of interleukin-6 by tocilizumab in the management of AA amyloidosis and chronic inflammatory disorders: a case series and review of the literatureThirusha Lane, Julian D Gillmore, Ashutosh D Wechalekar, et al.
Journal of Neuroimmunology|January 1, 1985
Immunological studies on the cerebrospinal fluid in neurological sarcoidosisJ D Mitchell, P L Yap, L A Milne, et al.
Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology|September 1, 1995
Bee venom immunotherapy induces a shift in cytokine responses from a TH-2 to a TH-1 dominant pattern: comparison of rush and conventional immunotherapyS M McHugh, J Deighton, A G Stewart, et al.
Clinical and Experimental Immunology|September 30, 2015
Further studies of the down-regulation by Factor I of the C3b feedback cycle using endotoxin as a soluble activator and red cells as a source of CR1 on sera of different complotypeP J Lachmann, E Lay, D J Seilly, et al.
The Journal of Experimental Medicine|June 1, 1993
Complement-mediated adipocyte lysis by nephritic factor seraP W Mathieson, R Würzner, D B Oliveria, et al.
Vox Sanguinis|January 1, 1983
Use of monoclonal anti-C3 antibodies to characterise the fragments of C3 that are found on erythrocytesP J Lachmann, D Voak, R G Oldroyd, et al.
Clinical and Experimental Immunology|April 1, 1978
The immunogloblin nature of nephritic factor (NeF)D M Scott, N Amos, J G Sissons, et al.
Clinical and Experimental Immunology|September 1, 1992
C7 M/N protein polymorphism typing applied to inherited deficiencies of human complement proteins C6 and C7R Würzner, N Rance, P C Potter, et al.
Clinical and Experimental Immunology|July 1, 1985
Simultaneous turnover of normal and dysfunctional C1 inhibitor as a probe of in vivo activation of C1 and contact activatable proteasesP Woo, P J Lachmann, R A Harrison, et al.
Pageof 43